Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Shitara Kohei; Ozguroglu Mustafa; Bang Yung-Jue; Di Bartolomeo Maria; Mandala Mario; Ryu Min-Hee; Fornaro Lorenzo; Olesinski Tomasz; Caglevic Christian; Chung Hyun C.; Muro Kei; Goekkurt Eray; Mansoor Wasat; McDermott Raymond S.; Shacham-Shmueli Einat; Chen Xinqun; Mayo Carlos; Kang S. Peter; Ohtsu Atsushi; Fuchs Charles S.

首页> 外文期刊>The Lancet >Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

【24h】

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

机译：Pembrozumab与先前治疗，晚期胃或胃食性结癌（Keynote-061）的患者（Keynote-061）：随机，开放标签，控制，第3阶段试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Patients with advanced gastric or gastro-oesophageal junction cancer that progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel in patients with advanced gastric or gastrooesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine.

机译：背景技术胃癌或胃食性胃癌癌症的患者进行化学疗法的结果差。我们将Pembrolizumab与紫杉醇与紫杉醇的患者与铂和氟嘧啶一起进行的先进的胃泌素或胃肠道结癌进行比较。

著录项

来源
《The Lancet》 |2018年第10142期|共11页
作者
Shitara Kohei; Ozguroglu Mustafa; Bang Yung-Jue; Di Bartolomeo Maria; Mandala Mario; Ryu Min-Hee; Fornaro Lorenzo; Olesinski Tomasz; Caglevic Christian; Chung Hyun C.; Muro Kei; Goekkurt Eray; Mansoor Wasat; McDermott Raymond S.; Shacham-Shmueli Einat; Chen Xinqun; Mayo Carlos; Kang S. Peter; Ohtsu Atsushi; Fuchs Charles S.;
展开▼
作者单位

Natl Canc Ctr Hosp East Kashiwa Chiba 2770882 Japan;

Istanbul Univ Cerrahpasa Sch Med Istanbul Turkey;

Seoul Natl Univ Coll Med Seoul South Korea;

Fdn IRCCS Ist Nazl Tumori Milan Italy;

Papa Giovanni XXIII Hosp Bergamo Italy;

Univ Ulsan Coll Med Asan Med Ctr Seoul South Korea;

Azienda Osped Univ Pisana Pisa Italy;

Maria Sklodowska Curie Mem Canc Ctr Warsaw Poland;

Fdn Arturo Lopez Perez Clin Alemana Santiago Santiago Chile;

Yonsei Univ Coll Med Yonsei Canc Ctr Seoul South Korea;

Aichi Canc Ctr Hosp Nagoya Aichi Japan;

HOPE Hamburg Germany;

Christie Hosp NHS Fdn Trust Manchester Lancs England;

Adelaide &

Meath Hosp Dublin Ireland;

Sheba Med Ctr Ramat Gan Israel;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Natl Canc Ctr Hosp East Kashiwa Chiba 2770882 Japan;

Smilow Canc Hosp Yale Canc Ctr New Haven CT USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial [J] . Shitara Kohei, Ozguroglu Mustafa, Bang Yung-Jue, The Lancet . 2018,第10142期

机译：Pembrozumab与先前治疗，晚期胃或胃食性结癌（Keynote-061）的患者（Keynote-061）：随机，开放标签，控制，第3阶段试验
2. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial [J] . WilkeH., MuroK., VanCutsemE., The lancet oncology . 2014,第11期

机译：先前接受过治疗的晚期胃或胃食管交界性腺癌（RAINBOW）患者的雷米库单抗联合紫杉醇与安慰剂联合紫杉醇：一项双盲，随机，3期临床研究
3. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial [J] . Herbst Roy S., Arkenau Hendrik-Tobias, Santana-Davila Rafael, The lancet oncology . 2019,第8期

机译：Ramucirumab Plus Pembrolizumab患者以前治疗的晚期非小细胞肺癌，胃肠癌癌或尿路上皮癌（JVDF）：多伐木菊，非随机化，开放标签，阶段1A / B试验
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Sexuality and gynaecological cancer: A randomised control trial to evaluate the effectiveness of a group psychoeducational intervention in improving the sexual health of women with gynaecological cancer treated with radiotherapy [D] . Jeffries, Sherryl Anne 2003

机译：性与妇科癌症：一项随机对照试验，旨在评估团体心理教育干预措施对经放射治疗的妇科癌症妇女改善性健康的有效性
6. Phase III randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 [O] . Y -J Bang, E Yañez Ruiz, E Van Cutsem, -1

机译：III期avelumab与医师选择化疗作为晚期胃癌或胃食管连接癌患者的三线治疗的随机试验：JAVELIN Gastric 300的初步分析
7. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group [O] . Kenro Hirata, Yasuo Hamamoto, Masahiko Ando, 2020

机译：每周Paclitaxel Plus Ramucirumab与每周Nab-Paclitaxel加上Ramucirumab与腹膜传播难以进行一线治疗 - P-SELECT试验（WJOG10617G）-A由西日本肿瘤学组进行随机化第二次审判

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

摘要

著录项

相似文献

相关主题

期刊订阅